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Abstract 
Objective 
To evaluate the psychometric properties of the Arm Activity Measure (ArmA), a 
patient-reported measure of active and passive function in the paretic upper limb. 
Design 
Psychometric evaluation study. 
Setting 
Two specialist rehabilitation and spasticity management services. 
Method 
Patients (n=92) with upper limb paresis were recruited from two specialist 
neurorehabilitation centres. Mean age 44.5(SD16.7).  Diagnostic distribution: stroke 
48(52%); other brain injury 28(31%); or other neurological condition 16(17%).    
Evaluation of convergent and divergent validity; unidimensionality, scaling, reliability 
(internal consistency and test-retest); responsiveness to change and feasibility of the 
ArmA were undertaken.  
Results 
Expected convergent and divergent relationships were seen with the Leeds Adult 
Spasticity Impact Scale and the Disabilities of Arm Shoulder and Hand (DASH) (rho 
0.5–0.63).  Principal components analysis (PCA) confirmed that active and passive 
function formed two separate constructs in each sub-scale.  Mokken analysis 
corroborated the findings of the PCA and demonstrated scaling using the monotone 
homogeneity model (Item H >0.5 for all items).  Cronbach’s alpha was 0.85 and 0.96 
respectively for the passive and active function sub-scales. Item level test-retest 
agreement ranged from 92-97.5% (quadratic-weighted Kappa 0.71-0.94).  In the 
subgroup treated for spasticity with botulinum toxin (n=58), the ArmA passive function 
scale identified a significant difference between responder and non-responder groups 
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(Mann Whitney U=0.85, p<0.01) Respondents reported the ArmA to be relevant (77%), 
easy to use (90%) and timely to complete (83% under 10 minutes). 
Conclusion 
The ArmA is a valid and reliable tool feasible for use in the evaluation of upper limb 
function in the context of treatment for spasticity. 
Word count 246 
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Introduction 
The complex nature of upper limb function presents a challenge for rehabilitation 
following neurological injury.  Some patients, with relatively mild injury, have potential 
to recover useful function such as the ability to use the hand to hold and manipulate 
objects (active function).  Others with more severe injury will continue to have a non-
functional upper limb, and may require assistance from another person (or their own 
non-affected arm) to care for the affected limb (passive function) [1]. There is a 
requirement for psychometrically robust instruments capable of reflecting clinically 
important change in clinical and research practice.   Outcome measures for treatments 
(such as botulinum toxin for spasticity) therefore need to cover both active and passive 
function, and should ideally reflect performance in real life, as opposed to that just 
observed in the clinic setting.  Patient-reported measures offer that advantage as well as 
minimising the burden of data collection for clinicians in a busy clinical environment. 
 
Reduction in spasticity has been demonstrated in a number of randomised trials 
following botulinum toxin (BoNT) and physical interventions [2-6].  Change in function 
has also been demonstrated by some authors for passive function [2, 7].  However due 
in part to limitations in currently available evaluation tools, these benefits have been 
harder to quantify [1, 8]. 
 
A previous systematic review of the published literature [9] demonstrated that, although 
a number of tools addressed aspects of either passive (Leeds Adult Spasticity Impact 
Scale - LASIS [2, 10]) or active function (Motor Activity Log - MAL [11]) none 
provided a comprehensive assessment of both parameters.  This led to the development 
of the Arm Activity measure (ArmA) – a new self-report measure of active and passive 
  5 
function in the upper limb.  Conceptualisation and development has been presented for 
publication elsewhere (reference in press).  The aim of this work was to evaluate its 
psychometric properties.  
 
Tools to measure outcome in rehabilitation should be subject to rigorous evaluation to 
confirm that they provide a valid and reliable assessment of the clinical parameters in 
question and to understand their metric properties.  The Scientific Advisory Board of 
the Medical Outcomes Trust has defined a set of attributes and review criteria against 
which the psychometric properties of health status and quality of life instruments may 
be judged, and these also form a useful framework for evaluation [12].  In the present 
article, we use this framework to provide a preliminary evaluation of the psychometric 
properties of the ArmA. Key criteria addressed were those for; construct validity, 
internal consistency, unidimensionality, scaling, test re-test reliability, responsiveness, 
interpretability and feasibility for use in routine clinical practice [12].   
 
Methods 
Ethical approval for the research programme was received (number 05/Q1604/110). 
 
The primary population for psychometric analysis was a consecutive cohort of patients 
(n=58) with upper limb spasticity presenting for treatment at two specialist 
rehabilitation units in London (Group 1).  However as the majority of these had severe 
upper limb impairment and intervention was primarily focused on passive function 
improvement, a second group (n=36) was purposively selected to expand the range of 
scores in the active function sub-scale (Group 2).  The participants in group 2 were 
recruited from patients with arm impairment seen at the same two rehabilitation units.  
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They were chosen on the basis that they were able to perform at least one of the active 
function activities within the ArmA.   
 
The setting for this work utilised two specialist rehabilitation and spasticity 
management services, both providing inpatient rehabilitation.  In addition, both services 
provided spasticity management clinics where botulinum toxin and physical 
interventions (e.g. splinting) were treatment options.  One service also provided 
spasticity intervention in an outreach capacity across a geographical region. 
 
Both groups were assessed at baseline (Time 1) and one day later (Time 2), for the 
evaluation of repeatability.  In addition, group 1 were assessed at 8 weeks (Time 3), 
following treatment for upper limb spasticity with botulinum toxin-A (BT-A) and 
physical therapy (PT).   
 
Data were collected at two sites. Both services provide inpatient rehabilitation, 
outpatient clinics including spasticity clinics, and managed patients through a spasticity 
management integrated care pathway (ICP). 
 
Power Calculation: The sample size was based on the criteria by Terwee and colleagues 
for evaluation of construct validity and test re-test reliability in groups of at least 50 
participants [12] and recommendations by Sim and Wright for sample size in reliability 
studies [13].   Assuming a null value for Kappa of 0.50 and a power of 90% a sample 
size of 88 was required.  In addition, this would conform to the recommendations for 
minimal total sample size of 50 participants for principal components analysis (PCA) 
[14].   
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Patients included were adults aged between 18 and 85 years with hemiplegic upper limb 
impairment affecting either active or passive function. In addition for Group 1: 
undergoing treatment for spasticity of the upper limb requiring BT-A intervention and 
PT.  Patients were excluded if they declined to participate or if their family and/or 
treating team declined on their behalf; or if they were unable to complete a 
questionnaire and no carer (professional or family) was available to undertake 
questionnaire completion on their behalf.   
 
Measures 
The measures used in this work were selected to allow comparison with the ArmA and 
test aspects of reliability and validity.  Measures for this purpose were selected either on 
the basis of an earlier systematic review [9] in the case of the functional measures or 
were widely utilised tools in research and clinical practice. 
 
The ArmA, LASIS and DASH were used to rate function by patients on the basis of 
activities performed over the preceding seven days. 
The Arm Activity Measure (ArmA) version 1 [15] is a patient or carer-rated 20-item 
measure of difficulty in passive and active arm function.  It comprises a seven-item 
Passive function subscale and thirteen-item Active function subscale, and uses a Likert 
scoring system between 0 (No difficulty) and 4 (unable to do task).  The Passive 
function sub-scale scores range from 0 (high function) to 28, and the Active function 
sub-scale scores range from 0 (high function) to 52 and was rated in this evaluation by 
patient and/or carer.  
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The Leeds Adult Spasticity Impact Scale (LASIS) [2, 10] is a 12-item measure of the 
impact of spasticity on arm function.  The LASIS has two sub-scales: a disability sub-
scale consisting of 12 items and a carer burden sub-scale consisting of 9 of the same 
items.  The LASIS uses a scale between 0 (No difficulty) and 4 (Unable to do task).  
The LASIS is applied as a structured interview with the patient completing all 12 items 
and the carer completing 9 of the same items.  A modified approach to scoring was 
used.  When patients and carers were both involved in the activity, the two scores were 
combined to produce a mean.  Items 1 to 9 were classified as passive function and items 
10 to 12 were classified as active function to allow comparison with the ArmA sub-
scales.   
The Disabilities of the Arm Shoulder and Hand (DASH) [16] questionnaire 
comprises 30 items, 21 of which are arm active function items, 5 are symptom related 
(for example pain) and the remaining 4 items review the impact of arm impairment on 
wellbeing and participation.  The DASH uses a scale between 0- none and 5- extreme 
difficulty for functional tasks.  The DASH is rated by the patient.  In this study for 
comparison with the ArmA an overall total for the measure was not produced, instead a 
total sum was produced for the active function items (items 1 to 21) for comparison 
with ArmA. 
The Barthel Index [17] is a measure of global disability and function.  The Barthel 
Index self-completion version was completed by patient or carer [18].  The measure 
comprises 10 items relating to personal ADLs, with each item scored on either a scale of 
0 to 2 or 0 to 3, giving a total score range from 0 (total dependence) to 20 (complete 
independence). 
The feasibility questionnaire was used to evaluate ease of use, relevance and value in 
the clinical situation.  It comprises one question each for a) time to complete, b) 
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relevance, b) usefulness of the active function section, d) usefulness of the passive 
function section and e) ease of completion.  Each question is rated on a 5-point Likert 
scale (e.g. for ease of completion: Very easy, Easy, Moderate, Difficult, Very difficult). 
A patient- and clinician-rating of goal attainment was used.  
Goal Attainment Scaling (GAS) [19] is a method of evaluating the extent to which 
patient’s individual goals are achieved in the course of intervention.  Scoring of GAS 
followed the approach proposed by Turner-Stokes [20], but was used in this study to 
identify ‘responders’ and ‘non responders’ to treatment for spasticity without 
calculation of the ‘T’ score. Patients were categorised as responders if they achieved a 
score of 0 to +2 for their primary treatment goal, and non-responders of they achieved a 
score of -1 to -2. 
The Modified Ashworth Scale (MAS) [21, 22] is a clinical measure of spasticity which  
forms a single item scale from 0 (no increase in muscle tone) to 4 (affected part rigid in 
flexion or extension), with an additional point at +1 (slight increase in muscle tone…) 
producing a six-point scale.  The MAS therefore provides a single score to represent 
spasticity.   
  
For group 1, goals were set prior to intervention using the GAS method for negotiating 
and recording goals [19, 20].  The ArmA, LASIS, DASH, Barthel Index, Modified 
Ashworth Scale and feasibility questionnaire were recorded at baseline.  The ArmA was 
repeated one day later to enable the evaluation of test-retest reliability.  Measures were 
then repeated at 8 weeks for group 1 to enable the testing of responsiveness following 
intervention.  In addition, achievement of goals set was recorded on a 5-point scale (-2 
to +2) [19, 20].   
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Patients gave written informed consent (n=63).  For those patients unable to consent, 
assent was given by the next of kin and the treating team (n=29).  A cleaned, validated 
dataset was exported to SPSS v15 [23] and STATA v10 [24] statistical packages for 
analysis. 
 
Analysis plan 
Whole sample: 
Floor and ceiling effects were assessed in the study population by considering the 
percentage of participants at either extreme of the subscales according to the criteria by 
Terwee and colleagues [12]. 
 
Construct validity was evaluated at Time 1 by comparing the passive and active 
function subscales of  the ArmA with the respective components of the LASIS and the 
DASH using the Spearman rank order correlation coefficient for convergent and 
divergent validity. 
 
Cronbach’s alpha (Time 1) was used to evaluate internal consistency.  Applying the 
criteria of Terwee and colleagues [12],  a positive rating for internal consistency was 
given when ratings for Cronbach’s alpha were between 0.70 and 0.95 [12].   
 
The unidimensionality of the ArmA sub-scales were initially evaluated using principal 
component analysis.  The results from principal component analysis were evaluated by 
initially considering Scree plots and Eigenvalues above 1 according to the criteria by 
Kaiser [25].  To confirm these findings, a Monte Carlo analysis was carried out 
according to the method by Horn [26].   
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Dimensionality was further explored using Mokken analysis and the relationship 
between different items in a scale can be explored using four assumptions.  The first is 
that items form a unidimensional scale.  The second is that item scores are locally 
independent, which means that item scores are independent within a group of persons 
with the same degree of the construct of interest [27].  The third assumption is that the 
‘item response function’ for each item is a non-decreasing function of the trait, which 
means each item would be expected to change in the same direction and to a related 
degree of change against the construct [27].  The fourth and final assumption measured 
is that ‘item response functions’ do not intersect, meaning that the items in the scale 
have an invariant hierarchical ordering across the latent trait when tested [27, 28].  
Assumptions one to three need to be satisfied to accept differentiation between 
respondents (Monotone Homogeneity – indicated by the H coefficient), and in addition, 
assumption four is required to accept differentiation between items in an ordinal scale 
(Double Monotonicity – indicated by the crit value together with the H index).  van 
Schuur identifies that no item in a unidimensional scale should have an item H below 
0.3 [29].  Mokken analysis (monotone homogeneity) was applied in this analysis a) to 
confirm the constructs of the ArmA, and b) as a preliminary evaluation of the ordinal 
scale structure of the items in the passive and active sub-scales.  Mokken analysis was 
applied as a preliminary and further evaluation of scaling properties is ongoing. 
 
Reproducibility (test re-test reliability) of ArmA was evaluated between Time 1 
(Baseline) and Time 2 (one day later) using Quadratic Weighted Kappa coefficients for 
test re-test reliability to comply with the recommendations of Terwee et al [12].   
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Feasibility was evaluated (Time 1) using a self-completed questionnaire administered 
following ArmA completion.  Patients and carers rated the timeliness, ease of use, 
relevance, and value in the clinical situation of the ArmA.   
 
Group 1 only: 
Responsiveness of the ArmA was evaluated between Time 1 (baseline) and Time 3 (8 
weeks) following BT-A injection.  Responsiveness was determined by comparing the 
change in ArmA between responder and non-responder groups using the non-parametric 
Mann-Whitney U test.  It was expected that the ArmA would identify a significant 
difference between the responder and the non-responder groups for passive function as 
defined by primary goal outcome (GAS) at Time 3 (8 weeks) following baseline.  A 
significant change was not expected in the group for active function, due to the lack of 
change identified in groups for active function who receive BT-A [30, 31]. 
 
Interpretability was based on the estimation of Minimal Important Change (MIC).  MIC 
was calculated using two methods; a criterion-based method and a distribution-based 
method.  The criterion-based method was produced by calculating the mean change in 
ArmA passive and active sub-scales in the responder group [32].  The distribution-based 
method [32] was calculated by using half the baseline (Time 1) standard deviation for 
ArmA as an estimate of MIC.  Both of these methods use parametric assumptions and 
therefore can only provide a preliminary indication of interpretability for the ArmA 
(which is an ordinal scale).   
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Results 
A total of 92 patients (58 Group 1, 34 Group 2) participated from 103 patients 
approached (63 Group 1, 40 Group 2).  Reasons for non-participation were not having 
BT-A intervention after assessment (n=4 in Group 1) or declining to participate (n=1 in 
Group 1, n=6 in Group 2).  See figure 1 for numbers of participants included at each 
stage of analysis. 
Insert Figure 1 about here 
The demographic characteristics of participants are described in Table 1. 
Insert Table 1 about here 
The medians and interquartile ranges for the measures used are shown in Table 2.   
Insert Table 2 about here 
ArmA passive function scores were distributed over the full range of the measure from 
0 to 28, with an increased frequency in the centre of the scale.  The modal score was 13, 
rated by 10 (11%) of participants.  In the active function sub-scale, a complete range of 
scores was produced at Time 1 from 0 to 52.  However a ceiling effect occurred with 
37% of scores for active function at the maximum point on the scale (52 – i.e. totally 
unable for all items). 
 
Construct validity (Assessed at time 1): The passive function sub-scale of the ArmA 
was found to correlate with passive function items in LASIS (Rho 0.50; p=0.01) 
demonstrating convergent validity, but not with active function items (Rho 0.02; p=0.9) 
demonstrating divergent validity as expected.  Similarly, the active function sub-scale 
correlated with LASIS active items (Rho 0.48; p=0.01) and DASH active items (Rho 
0.63; p=0.01) but did not with the LASIS passive function items (Rho 0.23; p=0.078) 
again demonstrating convergent and divergent validity in the expected pattern. 
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Internal consistency (Time 1): Cronbach’s alpha was 0.85 for the ArmA passive 
function sub-scale and 0.96 for active function demonstrating high internal consistency.   
 
Principal component analysis: The passive function sub-scale had one component 
with an Eigenvalue above 1 [25].  These results indicate a relatively coherent single 
construct of passive function confirmed with parallel analysis [26].  The active function 
sub-scale had two components with an Eigenvalue above 1 [25].  But using Horn’s 
method of parallel analysis, only the first factor was retained indicating a single 
principal component for active function [26].   
 
To support the single construct interpretation for the active and passive function sub-
scales, factor analysis was undertaken on the combined items from both sub-scales 
using principal components analysis followed by Promax rotation.  Although three 
components had Eigen values above 1, a Monte Carlo analysis was again conducted and 
confirmed two components representing the constructs.  Promax rotation was performed 
on the combined items and is shown in Table 3. 
Insert table 3 about here  
All 20 items were then plotted in 2 dimensional space shown in Figure 2. 
Insert figure 2 about here  
Figure 2 demonstrates that the passive function items group together as do the active 
function items, supporting two constructs.  However, one active function item (a81) 
“difficulty with balance when walking due to your arm” is more closely related to 
passive function rather than active function (see figure 2).   
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Mokken Analysis: The items in the passive function sub-scale produced an overall H 
coefficient for the scale of 0.48 with no individual item H-coefficients below 0.3 and 
fits criteria for a moderately strong unidimensional scale [29, 33], shown in Table 4.   
Insert table 4 about here  
Only item 6, had a crit value above 40 (actual value 43) outside the recommended range 
of crit values [33] indicating possible violations of monotonicity.  Although in this 
evaluation the aim was not to confirm double monotonicity, removal of items was 
explored to improve the overall item H and ensure crit values below 40.  Removal of 
items 7 and 6 resulted in a 5-item scale with an overall item H of 0.56 indicating a 
strong scale and highest crit value of 15 indicating no violations of monotonicity. 
 
The overall H coefficient for the active function total scale of 0.71 fits criteria for a 
strong unidimensional scale [29, 33] shown in Table 4.  The item with the lowest H 
index was again “difficulty with balance when walking due to your arm”, which had 
been discussed regarding its fit to either the passive or active function dimension.  No 
item, had a crit value above 40 outside the recommended range of crit values [33] 
indicating no violations of monotonicity. 
 
Test re-test reliability: Quadratic weighted Kappa coefficients for the ArmA sub-scale 
scores at time 1 and 2 were 0.90; CI 0.68-1.12 (passive function – Figure 3) and 0.93; 
CI 0.71-1.15 (active function – Figure 3).   
 
Insert Figure 3 about here 
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Item-level agreement ranged from 92% to 99%, and Quadratic weighted Kappa co-
efficients ranged from 0.71 to 0.94. The Kappa coefficients conformed to “substantial” 
or “almost perfect” criteria for all items [34].   
 
The ArmA identified a significant difference between responder and non-responder 
groups for the passive function sub-scale at 8 weeks (U = 98.5; p = 0.01). In this respect 
the ArmA was more responsive than the LASIS passive items (U = 127.0; p = 0.07), 
LASIS active items (U = 167.0; p = 0.39), DASH active items (U = 176.5; p = 0.92) or 
Barthel Index (U = 200.5; p = 0.17) none of which demonstrated any difference 
between the two groups.  
 
A significant difference was not shown for the active function sub-scale (U = 163.4; p = 
0.35).  However this was expected as only 4 of 58 participants in group 1 had a primary 
goal relating to active function.  This finding supports the responsiveness of the active 
function sub-scale in reflecting lack of change in the study group for the active function 
domain. 
 
Interpretability: Using the criterion-based method for assessing MIC, a clinically 
meaningful change would be 2.5 points on the passive function sub-scale and 1.1 on the 
active function sub-scale.  Using the distribution-based method, the corresponding 
figures were 3 and 2.5 points respectively. 
 
Feasibility, ease of completion was rated as ‘Very easy’ to ‘Moderately easy’ by 90% 
of patients or carers.  Completion of the ArmA was undertaken by 83% of participants 
in 10 minutes or under.  Relevance of the overall scale was rated by 77% of respondents 
as ‘Very relevant’ to ‘Moderately relevant’.  The active function sub-scale was rated as 
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‘Very useful’ to ‘Moderately useful’ by 71% of respondents and the passive function 
subscale by 88% of respondents.   
 
Discussion 
In this evaluation we present a preliminary psychometric evaluation of the ArmA in 
relation to the Medical Outcomes Trust Quality Criteria.[12]. Construct validity is 
supported, with confirmation of predicted moderate correlations of the ArmA with 
comparison measures addressing broadly similar parameters.  Internal consistency and 
test-retest reliability, were good in both ArmA sub-scales.  Principal Components 
Analysis (PCA) demonstrated one principal component for each of the sub-scales.  
Following Mokken analysis the unidimensionality of the two sub-scales is supported, 
although should be seen as preliminary evaluation due to the limited number of 
participants and the ceiling effect present in the active function data.  However the 
passive function sub-scale appears to be a unidimensional scale satisfying the monotone 
homogeneity model in its current form and may conform to double monotonicity when 
further evaluation is undertaken. 
 
In this study group, responsiveness was demonstrated in passive function, but could not 
be fully addressed for the active function subscale as few patients showed any change in 
this respect.  Our preliminary findings suggest that a change of 2-3 on the Passive 
function subscale represents clinically important change, but further evaluation is 
required for the active function subscale and in patient groups receiving other types of 
intervention.   
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To our knowledge, the ArmA is the only published self-report measure in the current 
literature that addresses both passive and active function of the paretic upper limb in a 
comprehensive manner.  The ArmA is designed for self-completion, making it 
potentially useful for patient and/or carer completion at a clinic or return by post 
following clinic visits with low clinician burden.  The ArmA but may also be used as a 
basis for structured interview undertaken at the clinic visit.  The findings presented here 
in the context of treatment for upper limb spasticity, provide preliminary psychometric 
support for its further testing and preliminary use.  
 
As noted above, a number of other tools have been developed and used in this context, 
but they also have limitations.  The LASIS [2, 10] primarily evaluates passive function, 
with a limited focus on active function and has not received formal psychometric testing 
to date. The Disability Assessment Scale (DAS) developed by Brashear and colleagues 
[21] is a clinician reported assessment and therefore does not represent the views of 
patients and carers.  Again DAS also does not address active function for the small 
minority of patients where active function improvement is possible following BT-A and 
physical interventions. 
 
The authors recognise a number of limitations to this study. 
Firstly, the addition of a purposively selected sample of participants (Group 2) to our 
consecutive cohort. This was done to extend representation of active function in our 
baseline evaluation of validity and reliability, but may have introduced some selection 
bias. Moreover, the fact that the additional sample was not undergoing specific 
treatment for their upper limb impairment meant that it was not possible to include them 
in the evaluation of responsiveness.  
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Secondly, the period during which this study was undertaken the knowledge base has 
grown with respect to the nature of goals for treatment in focal interventions for 
spasticity. A number of studies have demonstrated that goals related to passive tasks are 
both set more often and are more likely to be achieved than those relating to active 
function [35, 36].  Nevertheless qualitative analysis of goal attainment has demonstrated 
change over a range of patient experience, including active tasks [35]. It is therefore 
pertinent to have a tool that measures both aspects of function. 
 
Thirdly, previous work in patient-reported outcome measures [37],standardised 
measures in general practice [38] and rehabilitation [39] has emphasised that 
introduction of outcome measures into practice require clinicians to have ownership of 
the use of such measures.   
 
Fourthly, a further limitation is that the evaluation of feasibility was focused on patients 
and carers but not clinicians.  Patients and carers were prioritised as the most important 
and appropriate sources of data as they are the main users of the measure.  Although the 
views of clinicians were obtained during the ArmA development and were used 
extensively in item reduction and confirmation, they were not sought again formally 
during the testing of the ArmA.  Views from professionals may have been valuable in 
considering the impact of the ArmA in practice from the clinician’s perspective.  
 
Following psychometric evaluation of the ArmA, one passive function item excluded 
during development has been identified which merits further consideration regarding its 
place in the tool.  During item reduction, ‘cleaning around the affected elbow’ was 
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removed during the first round of Delphi consultation.  This item was removed on the 
recommendation of eight members of the consultation group (n=10).  However from a 
clinical perspective ‘Ease of elbow crease hygiene’ continued to be set as a goal (n=6) 
for participants in the psychometric evaluation.  This item has been added to the current 
version of the ArmA and revaluation of the properties of the modified measure is on-
going.  Further evaluation of the measurement scaling properties of the ArmA are also 
ongoing, including the active function sub-scale of the measure. 
 
Despite these limitations the study provides preliminary support for the ArmA as a 
valid, reliable and potentially responsive tool for the evaluation of treatment in upper 
limb spasticity. Further evaluation, including additional exploration of its scaling and 
measurement properties is now underway.  The ArmA is freely available to use and can 
be obtained with full instructions for completion, from the King’s College London, 
Department of Palliative Care, Policy and Rehabilitation web site 
(http://www.csi.kcl.ac.uk/arma.html). 
 
 
Clinical messages 
 To our knowledge, the ArmA is the only published self-report measure that 
addresses both passive and active function of the paretic upper limb in a 
comprehensive manner.   
 The ArmA is designed for self-completion, making it potentially useful for 
patient and/or carer completion at a clinic or return by post following clinic 
visits with low clinician burden.   
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 In the context of treatment for upper limb spasticity, the ArmA has demonstrated 
preliminary psychometric support for its further testing and initial use. 
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Tables 
 
Table 1 Demographic characteristics of the study population (n=92) 
Groups 
 
Group 1 (n=58) Group 2 (n=34) Combined (n=92) 
Mean age (years) 47 (SD=17.5) 42 (SD=15.8) 44.5 (SD=16.7) 
Male/female ratio 32:26 22:12 54:38 
 
Barthel Index - - 12 (2-15) 
 
 
DIAGNOSIS 
   
Stroke 30 (52%) 18 (53%) 48 (52%) 
Right hemisphere 13 (22%) 10 (28%) 23 (25%) 
Left hemisphere 17 (30%) 8   (24%) 25 (27%) 
Acquired brain 
injury 
22 (38%) 6   (18%) 28 (31 %) 
Traumatic  16 (28%) 5   (15%) 21 (23%) 
Anoxic 6   (10%) 1   (3%) 7   (8%) 
Other  6   (10%) 10 (29%) 16 (17 %) 
Multiple Sclerosis 4 (6%) 2 (6 %) 6 (7%) 
Motor neurone disease 1 (2%)  1 (1%) 
Encephalitis 1 (2%)  1 (1%) 
CNS Tumour  4 (12%) 4 (4%) 
Spinal cord injury  2 (6%) 2 (2%) 
Vasculitus  1 (3%) 1 (1%) 
Critical care neuropathy  1 (3%) 1 (1%) 
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Table 2: Median and inter-quartile range (IQR) for the study measures 
Measure  
 
 
Time 1 
Baseline  
Median (IQR) 
Time 2 
1 day 
Median (IQR) 
Time 3 
8 weeks 
Median (IQR) 
Group 
1+2 
(n=92) 
ArmA 
Passive 
12 (6-17) 13 (6-17) - 
ArmA  
Active 
48 (35-52) 47 (30-52) - 
Group 
1 
Only 
(n=58) 
ArmA 
Passive 
14 (10-18) - 13 (7-17) 
ArmA  
Active 
52 (48-52) - 51 (48-52) 
Barthel 
Index 
5 (0-15) - 5 (0-15) 
LASIS 
Passive 
items 
8 (4-16) - 8 (2-11) 
LASIS 
Active 
items 
0 (0-2) - 0 (0-2) 
DASH 
Active 
items 
105 (100-105) - 105 (99-105) 
 
  27 
 
Table 3 Item loadings for combined active and passive function sub-scales 
following Promax rotation with Kaiser normalisation. 
Item  Loading 1
st
 
component 
Loading 2
nd
 
component 
Passive Function   
1 Cleaning the palm of the hand 0.445 0.860 
2 Cutting finger nails 0.368 0.681 
3 Cleaning the armpit 0.449 0.615 
4 Positioning arm  0.396 0.784 
5 Putting arm through garment sleeve 0.353 0.830 
6 Putting on a glove 0.338 0.653 
7 Putting on a splint 0.329 0.651 
Active Function    
8 Do up buttons on clothing 0.860 0.493 
9 Pick up a glass, bottle, or can 0.848 0.524 
10 Use a key to unlock the door 0.889 0.484 
11 Write on paper 0.841 0.360 
12 Open a previously opened jar 0.853 0.521 
13 Eat with a knife and fork 0.856 0.435 
14 Hold an object still 0.708 0.476 
15 Difficulty with balance when walking 0.492 0.548 
16 Dial a number on home phone 0.934 0.477 
17 Tuck in your shirt 0.934 0.527 
18 Comb or brush your hair 0.884 0.466 
19 Brush your teeth 0.880 0.377 
20 Drink from a cup or mug 0.883 0.385 
Bold indicates the highest loading of each item onto one of the two components 
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Table 4 Mokken Analysis  
 Passive function sub-scale (n=92) 
Item Summary per item 
Mean Item H 
1 1.3 0.60 
2 2.2 0.48 
3 1.6 0.53 
4 1.2 0.40 
5 1.6 0.55 
6 2.2 0.43 
7 1.5 0.42 
 Scale H 0.48 
 Rho 0.85 
  
 Active function sub-scale (n=92) 
Item Summary per item 
Mean Item H 
1 2.5 0.51 
2 3.1 0.64 
3 3.4 0.73 
4 3.1 0.72 
5 3.3 0.73 
6 3.2 0.72 
7 3.2 0.79 
8 3.4 0.69 
9 3.3 0.72 
10 3.3 0.80 
11 3.3 0.73 
12 3.2 0.74 
13 3.4 0.76 
 Scale H 0.71 
 Rho 0.97 
  29 
Figure 1 Patients screened and response rate at each time point 
 
 
 
103 Possible participants screened 
(63 Group 1; 40 Group 2) 
Participants agreeing to participate: 
62 Group 1 
34 Group 2 
7 declined to participate 
(1 Group 1; 6 Group 2) 
Group 1 
4 participants did not receive 
BoNT and were excluded 
Time 2 – 1 Day following baseline 
44 Group 1 
34 Group 2 
Time 3 – 8 Weeks follow-up (Group 1 only) 
53 Participants 
 
Time 4 – 16 Weeks follow-up (Group 1 only) 
48 Participants 
14 Group 1 participants did not 
return questionnaires at 1 day. 
5 Group 1 participants did not 
attend for review. 
10 Group 1 participants did not 
attend for review. 
Participants at baseline: 
58 Group 1 
34 Group 2 
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Figure 2 Item plot in two-dimensional space for active and passive function sub-
scales combined (n=92) 
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Legend: The active function and passive items form two distinct groups apart from active function item 
a81 (“difficulty with balance when walking due to your arm”), which is more closely related to the 
passive function items. 
Passive function items 
Active function items 
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Figure 3 Test re-test reliability (Time 1 to Time 2) (n=78). 
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Appendix 1 - Summary of ArmA psychometric properties. 
Attribute Criteria Evaluation 
Validity Face Confirmed during pilot testing. 
Content Aim; population and target concepts: The ArmA was designed to provide a low burden measure of difficulty in active and passive 
arm function for patients undergoing spasticity management in the upper limb.   
Item selection and reduction; Item selection used a systematic review and patient selected items followed by Delphi consensus 
process with specialist clinicians and confirmed with a wider consultation.  
Interpretability of items: Understanding was confirmed during pilot testing [12]. 
Criterion-
related 
Not testable - no accepted gold standard measure for comparison currently exists.   
Construct 
(Correlation with 
other measures). 
Convergent: Passive function sub-scale correlated with passive function items from LASIS (Rho 0.5) and active function was 
correlated with active function items from LASIS (Rho 0.48) and active function items from DASH (Rho 0.63).   
Divergent: Passive function did not significantly correlate with DASH active items and LASIS active items. The active function 
subscale was not correlated with LASIS passive function items. 
 
Reproducibility Agreement  Percentage agreement ranged between 91.99 - 96.87 for the passive function scale and 92.15 - 97.52 for the active function scale. 
Test re-test 
Reliability 
(Weighted Kappa  
0.70 [12]) 
Quadratic Weighted Kappa coefficients for the passive function scale were between 0.71 - 0.90 and 0.70 - 0.94 for the active 
function scale.  
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Responsiveness  A significant difference was identified between responders and non-responders using the ArmA passive function sub-scale at 8 
weeks (U=98.5, P = 0.01), the active function sub-scale demonstrated that no change occurred in this domain as expected.   
 
Interpretability  Preliminary MIC was calculated using a criterion-based method (2.5) and a distribution-based method (3.0). 
Floor/ceiling effects  No significant floor or ceiling effects in the passive function sub-scale, but >15% ceiling effect in the active function sub-scale in 
the patient group used in this evaluation. 
Feasibility and 
Burden 
 
Time to 
administer 
Mean time for completion of ArmA was between 5-10 minutes and 83% were completed in 10 minutes or under.   
Ease of use  Ease of completion was rated as very easy, easy or moderate by 90 % of patients or carers.   
Relevance Relevance of the overall scale was rated by 77% of respondents as very relevant to moderately relevant.   
The active function sub-scale was rated as very useful to moderately useful by 71% of respondents and the passive function 
subscale by 88% of respondents. 
Acceptability Completion of ArmA was rated as very easy to moderate by 90 % of respondents and 77% of respondents rated it as relevant with 
a mean time for completion of between 5-10 minutes.   
Value The passive function subscale was rated by 88% of respondents as useful (very useful, useful or moderately useful). 
The active function subscale was rated by 71% of respondents as useful (very useful, useful or moderately useful).   
Alternative modes of administration Has been administered during testing as a self-completion questionnaire or as an interview (face-to-face or over the telephone).  
Only a small minority completed by interview or telephone and further validation of these methods will be needed. 
Cultural and language adaptations None currently available 
MIC - Minimal Important Change 
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Appendix 2 – Arm Activity Measure (ArmA)  
 
 Totalling section A and B separately produces a total score for each sub-scale of 
the measure. 
The sub-scales should not be combined. 
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In each column, please CIRCLE the amount of difficulty that you or your 
carer have experienced in doing the activity, over the last 7 days. 
 
Activities 
(affected arm)  
Difficulty 
0 = no difficulty 
1 = mild  
2 = moderate  
3 = severe difficulty  
4 = Unable to do 
activity 
Section A Caring for your affected arm (not using it in tasks or activities) 
 
1. Cleaning the palm of the hand 0 1 2 3 4 
2. Cutting finger nails 0 1 2 3 4 
3. Cleaning the armpit 0 1 2 3 4 
4. Cleaning the elbow crease 0 1 2 3 4 
5. Positioning arm on a cushion or support in sitting  
     (If never done circle 0) 
0 1 2 3 4 
6. Putting arm through a garment sleeve 0 1 2 3 4 
7. Putting on a glove (If never done circle 0) 0 1 2 3 4 
8. Putting on a splint (If never done circle 0) 0 1 2 3 4 
Section B Independently completing tasks or activities using your affected 
arm 
 
1. Difficulty with balance when walking due to your arm 0 1 2 3 4 
2. Hold an object still while using unaffected hand 0 1 2 3 4 
3. Open (affected hand) a previously opened jar  0 1 2 3 4 
4. Pick up a glass, bottle, or can 0 1 2 3 4 
5. Drink from a cup or mug 0 1 2 3 4 
6. Brush your teeth 0 1 2 3 4 
7. Tuck in your shirt 0 1 2 3 4 
8. Write on paper 0 1 2 3 4 
9. Eat with a knife and fork 0 1 2 3 4 
10. Dial a number on home phone 0 1 2 3 4 
11. Do up buttons on clothing 0 1 2 3 4 
12. Comb or brush your hair 0 1 2 3 4 
13. Use a key to unlock the door 0 1 2 3 4 
Total Score         Section A       
          Section B     
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Item 4 inserted following preliminary psychometric testing.   
 
